公开(公告)号：EP2963055B1

公开(公告)日：2019-05-15

申请号：EP14757574.0

申请日：2014-02-26

申请人： Hanmi Pharm. Co., Ltd.

发明人： JANG, Myung Hyun ,  KIM, Dae Jin ,  HWANG, Sang Youn ,  KIM, Hyun Uk ,  JUNG, Sung Youb ,  KWON, Se Chang

IPC分类号： A61K47/68 ,  C07K14/62 ,  C07K17/08 ,  A61K38/28 ,  A61P3/10

公开(公告)号：EP3442998A1

公开(公告)日：2019-02-20

申请号：EP17783033.8

申请日：2017-04-12

申请人： Cell And Molecular Tissue Engineering, LLC

发明人： KLUEH, Ulrike, W. ,  KREUTZER, Donald, L.

IPC分类号： C07K14/62 ,  A61K38/28 ,  A61K9/08

公开(公告)号：EP3399961A1

公开(公告)日：2018-11-14

申请号：EP16711707.6

申请日：2016-01-08

申请人： Amphastar Pharmaceuticals, Inc.

发明人： DING, Jeffrey ,  BO, Aili ,  LUO, Mary, Ziping ,  ZHANG, Jack, Yongfeng

IPC分类号： A61K9/00 ,  A61K38/28 ,  C07K14/62 ,  A61K9/14

CPC分类号： A61K38/28 ,  A61K9/0073 ,  A61K9/008 ,  A61K9/143 ,  C07K14/62

摘要： A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 μm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.

公开(公告)号：EP2925786B1

公开(公告)日：2018-10-03

申请号：EP12889309.6

申请日：2012-11-29

申请人： ST Pharm Co., Ltd.

发明人： BYUN, Young Ro ,  AHMED, Al-Hilal Taslim ,  JEON, Ok Cheol ,  MOON, Hyun Tae ,  YUN, Yisuk ,  KIM, Kyungjin

IPC分类号： A61K47/54 ,  A61K9/00 ,  A61K38/16 ,  A61K38/26 ,  A61K49/04 ,  A61K31/727 ,  B82Y5/00 ,  C07K14/605 ,  C07K14/62

CPC分类号： A61K31/727 ,  A61K9/0053 ,  A61K38/16 ,  A61K38/26 ,  A61K47/542 ,  A61K47/554 ,  A61K49/0423 ,  B82Y5/00 ,  C07K14/605 ,  C07K14/62

摘要： The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using said composition.

公开(公告)号：EP2914620B1

公开(公告)日：2018-08-08

申请号：EP13850542.5

申请日：2013-11-05

申请人： Case Western Reserve University

发明人： WEISS, Michael

IPC分类号： C07K14/62 ,  A61K38/28 ,  C12N15/17

CPC分类号： C07K14/62 ,  A61K38/00 ,  A61K38/28

摘要： A single-chain insulin analog containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of −1 or −2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR (SEQ ID NO: 18), SRRSR (SEQ ID NO: 17), VSRRSR (SEQ ID NO: 16), RVSRRSR (SEQ ID NO: 15), or SRVSRRSR SEQ ID NO: 13). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient.

公开(公告)号：EP3341401A1

公开(公告)日：2018-07-04

申请号：EP16757631.3

申请日：2016-08-24

申请人： Novo Nordisk A/S

发明人： MADSEN, Peter ,  MÜNZEL, Martin ,  HJØRRINGGAARD, Claudia Ulrich ,  HOSTRUP, Susanne ,  GLENDORF, Tine ,  NORRMAN, Mathias ,  FLEDELIUS, Christian

IPC分类号： C07K14/62 ,  A61K38/28

CPC分类号： C07K14/62 ,  A61K38/00

摘要： The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

公开(公告)号：EP2992094B1

公开(公告)日：2018-06-20

申请号：EP14791797.5

申请日：2014-05-01

申请人： Tolerion

发明人： ROEP, Bart, O. ,  ROBINSON, William, H. ,  UTZ, Paul ,  GARREN, Hideki ,  STEINMAN, Lawrence

IPC分类号： A61K48/00 ,  C07K14/62 ,  C12N15/85

CPC分类号： C07K14/62 ,  A61K39/0008 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/53 ,  A61K2039/54 ,  C12N15/85 ,  C12N2800/101 ,  C12N2800/107 ,  C12N2800/24

摘要： The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.

公开(公告)号：EP3328388A1

公开(公告)日：2018-06-06

申请号：EP16829537.6

申请日：2016-07-28

申请人： Société de commercialisation des produits de la recherche appliquée SOCPRA Sciences Santé et Humaines s.e.c.

发明人： ARDILOUZE, Jean-luc ,  GAGNON-AUGER, Maude ,  GOBEIL, Fernand ,  MENARD, Julie ,  BAILLARGEON, Jean-Patrice ,  BRASSARD, Pascal

IPC分类号： A61K31/5578 ,  A61K31/137 ,  A61K31/472 ,  A61K31/519 ,  A61K38/28 ,  A61P3/10 ,  C07C215/60 ,  C07C59/46 ,  C07D215/20 ,  C07D487/04 ,  C07K14/62

CPC分类号： A61K31/5578 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/472 ,  A61K31/519 ,  A61K31/557 ,  A61K31/5585 ,  A61K38/28 ,  A61K45/06 ,  A61P3/10 ,  C07D215/20 ,  C07D217/20 ,  C07D487/04 ,  C07K14/62 ,  A61K2300/00

摘要： The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

公开(公告)号：EP3197912A4

公开(公告)日：2018-06-06

申请号：EP15844864

申请日：2015-09-23

申请人： INDIANA UNIV RESEARCH & TECHNOLOGY CORPORATION

发明人： DIMARCHI RICHARD D ,  KOU BINBIN ,  ZHANG FA ,  MAYER JOHN P

IPC分类号： C07K14/62 ,  A61K38/28

CPC分类号： C07K14/62 ,  A61K38/00 ,  A61K38/28 ,  A61K47/00 ,  A61K47/48023 ,  A61K47/48046 ,  A61K47/48815

摘要： Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

公开(公告)号：EP2838915B1

公开(公告)日：2018-05-30

申请号：EP13726299.4

申请日：2013-04-19

申请人： Chemical & Biopharmaceutical Laboratories Of Patras SA

发明人： Barlos, Kleomenis K. ,  Barlos, Konstantinos ,  Gatos, Dimitrios ,  Ziovas, Michail ,  Liopyris, Efstathios

IPC分类号： C07K14/62

CPC分类号： C07K14/62 ,  C07K1/042 ,  Y02P20/55

摘要： The present application discloses the preparation of peptides, including insulin and insulin derivatives, using efficient methods for solid-phase and solution phase peptide synthesis.